ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Ann Thorac Surg 2008;85:571-579. doi:10.1016/j.athoracsur.2007.10.034
© 2008 The Society of Thoracic Surgeons

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Rony Atoui
Dominique Shum-Tim
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Atoui, R.
Right arrow Articles by Shum-Tim, D.
PubMed
Right arrow Articles by Atoui, R.
Right arrow Articles by Shum-Tim, D.
Related Collections
Right arrow Molecular biology


Original Articles: Cardiovascular

Marrow Stromal Cells as Universal Donor Cells for Myocardial Regenerative Therapy: Their Unique Immune Tolerance

Rony Atoui, MD, MSa, Juan-Francisco Asenjo, MDb, Minh Duong, BSa, Guangyong Chen, MDa, Ray C.-J. Chiu, MD, PhDa, Dominique Shum-Tim, MD, MSa,*

a Division of Cardiac Surgery, McGill University Health Center, Montreal, Quebec, Canada
b Department of Anesthesia, McGill University Health Center, Montreal, Quebec, Canada

Accepted for publication October 8, 2007.

* Address correspondence to Dr Shum-Tim, Division of Cardiothoracic Surgery, McGill University Health Center, 1650 Cedar Ave, Suite C9-169, Montreal, Quebec, H3G 1A4, Canada (Email: dshumtim{at}yahoo.ca).

Background: Recently rodent and porcine bone marrow stromal cells (MSCs) have been reported to be uniquely immune tolerant. To confirm these findings in human cells, we tested whether human MSCs are also immune tolerant, such that they can be used as universal donor cells for myocardial regenerative therapy.

Methods: Immunocompetent female rats underwent coronary ligations (n = 90). In group I, lacZ-labeled male human MSCs were implanted into the peri-infarcted area. In groups II, III, and IV, isogeneic rat MSCs, culture medium, or human fibroblasts were injected, respectively. Echocardiography was carried out to assess cardiac function, and the specimens were examined serially for up to 8 weeks with immunohistochemistry, fluorescent in situ hybridization, and polymerase chain reaction to examine MSCs survival and differentiation.

Results: Human MSCs survived within the rat myocardium for more than 8 weeks without immunosuppression. Furthermore, the implanted MSCs significantly contributed to the improvement in ventricular function and attenuated left ventricular remodeling. No cellular infiltration characteristic of immune rejection was noted in contrast to group IV.

Conclusions: Human MSCs survived within this xenogeneic environment, and contributed to the improvement in cardiac function. Our findings support the feasibility of using these cells as universal donor cells for xenogeneic or allogeneic cell therapy, as they can be prepared and stored well in advance for urgent use. Allogeneic MSCs from healthy donors may be particularly useful for severely ill or elderly patients whose own MSCs could be dysfunctional.




This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
R. Atoui, D. Shum-Tim, and R. C.J. Chiu
Myocardial regenerative therapy: immunologic basis for the potential "universal donor cells".
Ann. Thorac. Surg., July 1, 2008; 86(1): 327 - 334.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
Y. L. Tang
Invited Commentary
Ann. Thorac. Surg., February 1, 2008; 85(2): 580 - 580.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 by The Society of Thoracic Surgeons.